Rethinking DMT: Algernon Pharmaceuticals’ Novel Approach to Stroke Treatment
The pharmaceutical industry is famous for its high R&D costs. But there are low-risk, capital-efficient alternatives to new drug development. Algernon Pharmaceuticals Inc. is exploring one such option: drug repurposing. Its current work includes research into microdoses of DMT as a treatment for acute stroke. Algernon CEO, Christopher J. Moreau, gives us some insight in this interview.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed